43 results
8-K
EX-10.1
COYA
Coya Therapeutics Inc
20 May 24
Coya Therapeutics Announces $5 Million Strategic
5:00pm
and safety, product quality and safety and employment and labor matters, except in each case as could not have or reasonably be expected to result
8-K
EX-99.1
COYA
Coya Therapeutics Inc
20 May 24
Coya Therapeutics Announces $5 Million Strategic
5:00pm
for 48 consecutive weeks and were evaluated for safety and tolerability, Treg function, serum biomarkers of oxidative stress and inflammation … trials; the ability of our product candidates to achieve applicable endpoints in the clinical trials; the safety profile of our product candidates
8-K
EX-99.1
COYA
Coya Therapeutics Inc
9 May 24
Coya Therapeutics Provides a Corporate Update and Reports Unaudited First Quarter 2024 Financial Results
4:20pm
and dosing in our preclinical or clinical trials; the ability of our product candidates to achieve applicable endpoints in the clinical trials; the safety
8-K
EX-99.1
6s2o64
19 Mar 24
Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2023 Financial Results
8:21am
424B3
v7vzq7y 5dq
16 Jan 24
Prospectus supplement
4:06pm
S-3
dej0kl wuss8dui
4 Jan 24
Shelf registration
4:46pm
8-K
EX-99.1
nxsoa
20 Dec 23
Departure of Directors or Certain Officers
8:35am
8-K
EX-10.1
d7umt3
6 Dec 23
Entry into a Material Definitive Agreement
7:30am
8-K
EX-99.1
7533u2
6 Dec 23
Entry into a Material Definitive Agreement
7:30am
8-K
EX-99.1
26e 0nbbseymk5
8 Nov 23
Coya Therapeutics, Inc. Provides Business Update and Reports Q3 2023 Unaudited Financial Results
9:03am
8-K
EX-99.1
3sa n744af1
21 Aug 23
Former CEO and Chairman of the Board of Bayer Pharma AG, Dieter Weinand, joins Coya’s Board of Directors
5:01pm
8-K
EX-99.1
ps26i07w
8 Aug 23
Coya Therapeutics, Inc. Provides Business Update and Reports Q2 2023 Unaudited Financial Results
7:05am
8-K
EX-99.1
wie01z6l
12 Jun 23
Regulation FD Disclosure
5:01pm
8-K
EX-99.1
y8zkfpzk
16 May 23
Regulation FD Disclosure
7:47am